- Home
- ANGH vs INKT Comparison
ANGH vs INKT Comparison
Compare ANGH & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- INKT
- Stock Information
- Founded
- ANGH 2012
- INKT 2017
- Country
- ANGH United Arab Emirates
- INKT United States
- Employees
- ANGH N/A
- INKT N/A
- Industry
- ANGH Telecommunications Equipment
- INKT Medicinal Chemicals and Botanical Products
- Sector
- ANGH Consumer Discretionary
- INKT Health Care
- Exchange
- ANGH Nasdaq
- INKT Nasdaq
- Market Cap
- ANGH 32.1M
- INKT 28.9M
- IPO Year
- ANGH N/A
- INKT 2021
- Fundamental
- Price
- ANGH $0.49
- INKT $7.01
- Analyst Decision
- ANGH
- INKT Strong Buy
- Analyst Count
- ANGH 0
- INKT 2
- Target Price
- ANGH N/A
- INKT $37.50
- AVG Volume (30 Days)
- ANGH 12.7K
- INKT 14.7K
- Earning Date
- ANGH 07-15-2025
- INKT 08-12-2025
- Dividend Yield
- ANGH N/A
- INKT N/A
- EPS Growth
- ANGH N/A
- INKT N/A
- EPS
- ANGH N/A
- INKT N/A
- Revenue
- ANGH $78,093,405.00
- INKT N/A
- Revenue This Year
- ANGH N/A
- INKT N/A
- Revenue Next Year
- ANGH N/A
- INKT N/A
- P/E Ratio
- ANGH N/A
- INKT N/A
- Revenue Growth
- ANGH 88.72
- INKT N/A
- 52 Week Low
- ANGH $0.42
- INKT $4.56
- 52 Week High
- ANGH $1.08
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- ANGH 43.39
- INKT 43.60
- Support Level
- ANGH $0.47
- INKT $6.80
- Resistance Level
- ANGH $0.52
- INKT $7.55
- Average True Range (ATR)
- ANGH 0.02
- INKT 0.34
- MACD
- ANGH 0.00
- INKT -0.03
- Stochastic Oscillator
- ANGH 27.27
- INKT 13.29
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.